Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors

Nanotheranostics. 2021 Jan 19;5(2):182-196. doi: 10.7150/ntno.52361. eCollection 2021.

Abstract

Enhanced vascular permeability in tumors plays an essential role in nanoparticle delivery. Prostate-specific membrane antigen (PSMA) is overexpressed on the epithelium of aggressive prostate cancers (PCs). Here, we evaluated the feasibility of increasing the delivery of PSMA-targeted magnetic nanoparticles (MNPs) to tumors by enhancing vascular permeability in PSMA(+) PC tumors with PSMA-targeted photodynamic therapy (PDT). Method: PSMA(+) PC3 PIP tumor-bearing mice were given a low-molecular-weight PSMA-targeted photosensitizer and treated with fluorescence image-guided PDT, 4 h after. The mice were then given a PSMA-targeted MNP immediately after PDT and monitored with fluorescence imaging and T2-weighted magnetic resonance imaging (T2-W MRI) 18 h, 42 h, and 66 h after MNP administration. Untreated PSMA(+) PC3 PIP tumor-bearing mice were used as negative controls. Results: An 8-fold increase in the delivery of the PSMA-targeted MNPs was detected using T2-W MRI in the pretreated tumors 42 h after PDT, compared to untreated tumors. Additionally, T2-W MRIs revealed enhanced peripheral intra-tumoral delivery of the PSMA-targeted MNPs. That finding is in keeping with two-photon microscopy, which revealed higher vascular densities at the tumor periphery. Conclusion: These results suggest that PSMA-targeted PDT enhances the delivery of PSMA-targeted MNPs to PSMA(+) tumors by enhancing the vascular permeability of the tumors.

Keywords: enhanced permeability and retention (EPR) effect; magnetic nanoparticle delivery; magnetic resonance imaging (MRI); photodynamic therapy (PDT); prostate cancer.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antigens, Surface / metabolism*
  • Cell Line, Tumor
  • Glutamate Carboxypeptidase II / metabolism*
  • Humans
  • Magnetic Resonance Imaging / methods
  • Magnetite Nanoparticles / administration & dosage*
  • Male
  • Mice
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use
  • Prostatic Neoplasms / drug therapy*
  • Xenograft Model Antitumor Assays

Substances

  • Antigens, Surface
  • Magnetite Nanoparticles
  • Photosensitizing Agents
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II